|Day Low/High||50.01 / 51.25|
|52 Wk Low/High||42.40 / 66.04|
Not to be outcome by a unicorn company, the unicorn sector of the markets, cannabis, is unleashing a blitzkrieg of news this morning. On the acquisition side, Cresco Labs is buying Origin House (CannaRoyalty) this morning for a small premium. It app...
While the two tobacco giants have similar yields, both also have very different businesses, with different growth potential in the years ahead.
Revenue is where it's at for cannabis in 2019.
A huge week is coming up for these well-known stocks.
Investors can gain exposure to the high-flying cannabis industry without taking on undue risks.
The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.
In this day and age, companies must be 'disruptors' or get left in the dust.
I know that Nelson is fascinated by the medicinal properties chiefly as a replacement for opioids, the scourge of this country.
Aurora's prominent partner could be cannabis' key to breaking into consumer segments.
With shares breaking above the recent, albeit small, pennant, there might be reason for optimism.
GSKY bulls watched as the stock lost two-thirds of its value from its post-IPO high and are now looking for news to turn the bearish tide.
And why I won't recommend any other stocks in these markets, right now.
Examining the influential short-sellers' big winners and losers provides important insights into trading and investing.
These stocks have grown their dividend for years but the yield has now reached levels of attraction.
Many see the Fed as done for the year. Never assume. Read the words as they are written.
Before I bid everyone here at the Diary good day and plug into the earnings reports and corresponding conference calls I listed in my last post, here are some of the reports hitting the tape Thursday morning that I'll be watching and things I'll be ...
Altria's recent selloff should be welcomed by both value seekers and those desiring quarterly income to live on.
Any logical evaluation of this stock suggests low risk and tremendous upside.
Any logical evaluation of British American Tobacco suggests low risk and tremendous upside.
Canopy Growth's smoking engine won't necessarily ensure smooth sailing for Constellation.
What matters here is the ability to innovate, market, and sell.
Establishing who the stragglers are and what impact they might have in the future is the key at this point.
I'd be most interested in buying this name after a cap raise which I expect in the first quarter of 2019.
The buy-in from other companies into the space has been far larger.
After Altria's investment in Cronos Group, which cannabis company will be the next target?
Paul Simon was right about one thing. You know the nearer your destination, the more your slip slidin' away. The more markets slip on these awful days, the nearer we are getting to our destination. Is that a good thing? I think I'll stick to my defe...
The tobacco giant is being threatened on two fronts: e-cigarettes in the form of Juul and cannabis.